Journal
SCIENCE ADVANCES
Volume 8, Issue 38, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abq0866
Keywords
-
Categories
Funding
- Uehara Memorial Foundation
- Harvard Stem Cell Institute Seed Grant
- NIH [UH3TR002155, DP2EB029388/DK133821, U01EB028899/DK127587, UC2DK126023]
Ask authors/readers for more resources
By integrating organoids with organ-on-a-chip technology, this study has demonstrated the potential of organoid-on-a-chip models in unraveling disease pathology and discovering therapeutic targets for autosomal recessive polycystic kidney disease.
Organoids serve as a novel tool for disease modeling in three-dimensional multicellular contexts. Static organoids, however, lack the requisite biophysical microenvironment such as fluid flow, limiting their ability to faithfully recapitulate disease pathology. Here, we unite organoids with organ-on-a-chip technology to unravel disease pathology and develop therapies for autosomal recessive polycystic kidney disease. PKHD1-mutant organoids-on-a-chip are subjected to flow that induces clinically relevant phenotypes of distal nephron dilatation. Transcriptomics discover 229 signal pathways that are not identified by static models. Mechanosensing molecules, RAC1 and FOS, are identified as potential therapeutic targets and validated by patient kidney samples. On the basis of this insight, we tested two U.S. Food and Drug Administration-approved and one investigational new drugs that target RAC1 and FOS in our organoid-on-a-chip model, which suppressed cyst formation. Our observations highlight the vast potential of organoid-on-a-chip models to elucidate complex disease mechanisms for therapeutic testing and discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available